Company news

Noxopharm Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Dedicated Septic Shock Company Established

November 5, 2020

Noxopharm Quarterly Activities Report & Appendix 4C

October 14, 2020

Noxopharm Loan Terms Amended to Benefit Company

October 5, 2020

First COVID-19 Patient Treated in Veyonda Study

October 1, 2020

Veyonda COVID-19 Study Approved For Immediate Start

August 31, 2020

Appendix 4E and Audited Financial Statements FY2020

August 30, 2020

Peer-Reviewed Publication Strengthens Case For Veyonda

August 10, 2020

Noxopharm 2020 June quarter Appendix 4C & Activities Report

July 28, 2020

Noxopharm Reports Idronoxil Achieves Major Industry Goal of Converting ‘Cold’ Tumors to ‘Hot’

July 23, 2020

Data Shows Idronoxil Holds Key to Problem of COLD Cancers

July 19, 2020

COVID-19 Trial Program to Commence in Europe

June 18, 2020

Pro-rata Non-Renounceable Rights Issue Fully Allocated

June 14, 2020

ASCO 2020 Highlights NOX66 Potential in Late-Stage Cancer

May 31, 2020

FDA allows Veyonda Pre-IND Submission for COVID-19

May 19, 2020

Entitlement Offer Prospectus

May 13, 2020

$7.9 Million Fully Underwritten Entitlement Offer Announced

May 12, 2020

Noxopharm March 2020 Quarterly Report & Appendix 4C

April 30, 2020

Abscopal Responses Achieved in Prostate Cancer

April 29, 2020

Pipeline Expands With Potential New Brain Cancer Treatment

April 22, 2020

Approval to be sought for COVID-19 Clinical Study in U.S.

April 20, 2020

Noxopharm Investigating Potential COVID-19 Treatment

March 31, 2020

Veyonda Awarded First Allowed Patent Application

March 16, 2020

LuPIN Prostate Cancer Trial Fully Recruited

March 2, 2020

Half Year Accounts and Chairman Letter

February 25, 2020

FDA grants IND approval to Veyonda

February 20, 2020

Noxopharm Alliance With GenesisCare

February 17, 2020

LuPIN Trial Interim Results Indicate Striking Survival Benefit

February 14, 2020

$8.1M Financing & Re-Set of Capital Structure

February 13, 2020

Noxopharm Dec 2019 Appendix 4C

January 30, 2020

Listing of Nyrada Inc. spin-off on ASX

January 16, 2020

DARRT-1 Clinical Data Webinar

December 19, 2019

Nyrada IPO Offer Fully Subscribed

December 16, 2019

Lodgement of Nyrada Inc Supplementary Prospectus

December 8, 2019

Nyrada Inc Initial Public Offering Opens

December 3, 2019

Positive DARRT-1 Data in Late-Stage Prostate Cancer

December 2, 2019

Lodgement of Nyrada Inc Prospectus - Initial Public Offering

November 26, 2019

Noxopharm Announces Appointment of Chief Commercial Officer

November 6, 2019

Appendix 4C - Quarterly

October 29, 2019

Dr Graham Kelly to Assume CEO Role

October 27, 2019

Durable Anti-Cancer Effect Confirmed in DARRT-1 Study

October 20, 2019

Potential Fundamental Change in Treatment of Brain Cancer

October 17, 2019

Further Review Shows Major Clinical Benefits from Veyonda

September 30, 2019

Veyonda and Radiotherapy Profiled at Key Oncology Meeting

September 17, 2019

Appendix 4E and Audited Financial Statements FY19

August 29, 2019

More Evidence that Veyonda Enhances RT in Prostate Cancer

August 27, 2019

NOX Receives FY19 Federal Government R&D Tax Rebate

August 23, 2019

Pre-Clinical Evidence Confirms Veyonda Abscopal Effect

August 21, 2019

Noxopharm August 2019 Corporate Presentation

August 6, 2019

NOX Announces AU$26 Million Funding Facility

July 19, 2019

Conference Hears of Positive Interim Data from LuPIN Trial

June 25, 2019

← Newer news releases · Older news releases →

Decks

The 5 newest of 53 decks. Every deck is listed under its year.